Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View PlansCash Conversion
1.09x
JUBLPHARMA's operating cash flow exceeded net income in FY 2025, indicating earnings are backed by actual cash generation.
Free Cash Flow
₹-435.00M
JUBLPHARMA's free cash flow was negative at ₹-435.00M in FY 2025, down 159.1% from FY 2024. The company spent more on capital investments than it generated from operations.
Dividend Coverage
-0.5x
JUBLPHARMA's free cash flow did not fully cover dividends in FY 2025. The company may be funding dividends from reserves or borrowings.
CapEx Intensity
104.1%
Capital expenditure consumed 104.1% of operating cash flow in FY 2025 for JUBLPHARMA, typical of capital-intensive industries.
Hover the chart icon for YoY change.
| Item | Chart | 2024 | 2025 |
|---|---|---|---|
| Net Income | 1.71B | 9.81B | |
| Cash flow Operating Activities | 9.71B | 10.72B | |
| Investments in PPE | -8.98B | -11.16B | |
| Cash flow Investing Activities | -6.08B | 4.88B | |
| Dividend Paid | -798.00M | -796.00M | |
| Cash flow Financing Activities | -4.33B | -14.53B | |
| Cash at beginning of period | 10.14B | 9.56B | |
| Cash at end of period | 9.56B | 10.88B | |
| Free Cash Flow | 736.00M | -435.00M |
Values are shown in millions (M) and billions (B). All amounts are in Indian Rupees (₹).
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: Mar-2025